{"filing":{"accession_number":"0001193125-26-264000","cik":"0000921299","ticker":"KYNB","company_name":"KYNTRA BIO, INC.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"kynb-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526264000/kynb-20260602.htm"},"events":[{"id":5936,"run_id":5209,"accession_number":"0001193125-26-264000","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This disclosure reports the final receipt of $4.0 million from AstraZeneca as the second and final holdback under the Share Purchase Agreement for the sale of Kyntra Bio's China operations, which closed on August 29, 2025 for approximately $220 million in total consideration. The completion of all post-closing payments under a material acquisition/disposition agreement is a significant event affecting the company's cash position and the finalization of a major transaction.","company_name":"KYNTRA BIO, INC.","ticker":"KYNB","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5636,"accession_number":"0001193125-26-264000","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure reports the final receipt of $4.0 million from AstraZeneca as the second and final holdback under the Share Purchase Agreement for the sale of Kyntra Bio's China operations, which closed on August 29, 2025 for approximately $220 million in total consideration. The completion of all post-closing payments under a material acquisition/disposition agreement is a significant event affecting the company's cash position and the finalization of a major transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T21:06:06.251018+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5636,"accession_number":"0001193125-26-264000","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure reports the final receipt of $4.0 million from AstraZeneca as the second and final holdback under the Share Purchase Agreement for the sale of Kyntra Bio's China operations, which closed on August 29, 2025 for approximately $220 million in total consideration. The completion of all post-closing payments under a material acquisition/disposition agreement is a significant event affecting the company's cash position and the finalization of a major transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T21:06:06.251018+00:00","company_name":"KYNTRA BIO, INC.","ticker":"KYNB","filing_date":"2026-06-09"}]}